Glaxo Smith Kline results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements.
Net profit-185 millionEGP
Total assets3.19 billionEGP
Shareholders' equity1.73 billionEGP
Operating cash flow632 millionEGP
In short
- Glaxo Smith Kline's net profit for Q4 2022 was about -185 million EGP.
- Total assets at the end of Q4 2022 were about 3.19 billion EGP, and shareholders' equity about 1.73 billion EGP.
- Operating cash flow for Q4 2022 was positive at 632 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit-185 million——
Gross profit374 million——
Total assets3.19 billion——
Total liabilities1.46 billion——
Shareholders' equity1.73 billion——
Total liabilities and equity3.19 billion——
Operating cash flow632 million——
Investing cash flow-227 million——
Financing cash flow58.96 million——
Net change in cash464 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy